At Chiesi, initiatives in this area are spearheaded by Chiesi Global Rare Diseases, the Group’s business unit focused on research, development and commercialization of therapies for rare and ultra rare conditions.

The transaction is Chiesi’s most substantial acquisition to date in value terms and reflects the company’s long term ambitions, and represents an important milestone in its strategy in Rare Diseases, reinforcing its commitment across generations to improving the lives of people living with rare conditions, it states.

“This acquisition supports our strategy to accelerate impact in rare diseases by bringing together science, innovation and expertise to address areas of highest unmet need. KalVista’s proven drug discovery and development capabilities, combined with our global footprint and operational excellence, will enable us to deliver innovation to patients at greater scale,” says Jean-Marc Bellemin, Chiesi Group’s CFO, and Interim Group CEO (from 15 May 2026).